Brian Mehling, MD, (R) and Dongecheng Wu, MD, Ph.D., (L) during the stem cell applications at BHI Jamaica.
Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is also spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells. Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education...
read moreStem Cells Quality Reports
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal...
read moreBRIAN MEHLING, MD RECEIVES 2020 BEST OF WEST ISLIP AWARD
Brian Mehling, MD, an orthopedic trauma surgeon, has been selected for the 2020 Best of West Islip Award in the Physicians & Surgeons category by the West Islip Award Program. Each year, the West Islip Award Program identifies companies and individuals that have achieved exceptional marketing success in their local community and business category. They enhance the positive image of small business through service to their customers and the community. As a result, the recipients help make the West Islip area a great place to live, work,...
read moreBHI THERAPEUTIC SCIENCES SCIENTIFIC ADVISORY BOARD CHAIRMAN RECEIVES APPROVAL TO USE STEM CELL PRODUCT IN CLINICAL TRIALS
A Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) product, developed by Wuhan Hamilton Biotechnology Co., Ltd., recently passed inspection by the China National Institute for Food and Drug Control. As a result, the UC-MSCs are a qualified product for application in clinical trials. Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is...
read moreStem cells could be the medical innovation of the century
This article is part of the World Economic Forum Annual Meeting (Davos-Klosters, Switzerland 21—24 January 2020) The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases. Today, six of...
read moreBRIAN MEHLING, MD TO PRESENT SPINAL CORD STEM CELL RESEARCH AT ANNUAL MEETING OF THE SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS
Brian Mehling, MD has been invited to present his research at the 17th Annual World Congress of the Society for Brain Mapping and Therapeutics being held at the JW Marriott, in Los Angeles, California from Friday March 20-Sunday March 22. The conference will bring together physicians, scientists, policy makers, funding agencies and industry to further the advances and applications in brain and spinal cord mapping and image guided therapies (operative and non-operative). Dr. Mehling is the founder and chief medical officer of BHI...
read moreWORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 50TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS
The 2020 World Economic Forum (WEF) in Davos will explore the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology.The US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, MSc, President of BHI Slovakia ; Alan...
read moreBRIAN MEHLING, MD AND BHI THERAPEUTIC SCIENCES TO PRESENT RESEARCH AT AAOS ANNUAL MEETING
Orthopedic surgeon Brian Mehling, MD and his research team at BHI Therapeutic Sciences will exhibit at the American Academy of Orthopedic Surgeons 2020 Annual Meeting, March 24 – 28, at the Orange County Convention Center in Orlando, Florida. The team will present the results of their study entitled “Adipose Tissue-Derived Stromal Vascular Fraction Cells Application in Subjects with Osteoarthritis and Rheumatoid Arthritis: Retrospective Chart Review Study.” Their results will be presented at booth #1004 located in the West Concourse of...
read moreBlue Horizon International Ambassador Lance Palmer becomes PFL’s first multi-millionaire
On December 31, 2019, Lance Palmer celebrated the new year by defeating Alex Gilpin in a unanimous decision win at Madison Square Garden. The victory gave Palmer the featherweight title for the second year in a row, and another million dollars.Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training. Palmer received his treatments at the BHI...
read moreBlue Horizon International exhibits at World Congress on Anti-Aging Medicine in Las Vegas
Blue Horizon International (BHI), Alpha Blu Skin Care, BHI Therapeutic Sciences, and BHI Rejuve participated in the 27th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2019. Brian Mehling, M.D. , Founder and Chief Medical Officer of BHI was joined by Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; Alan DaSilvaPereira, President of BHI Brazil; Fidel Desmar, Clinical Research Coordinator; Ralph Moffetone and John-David Grayson from Industrial Motion...
read more
